Understanding Drug Interactions
A clinical overview of drug–drug interaction mechanisms, clinical significance assessment, and prevention strategies for pharmacists, prescribers, and students.
Interaction Mechanisms
Drug–drug interactions (DDIs) are broadly divided into pharmacokinetic and pharmacodynamic categories. Most clinically significant interactions are pharmacokinetic, mediated by changes in drug metabolism or transport that alter systemic exposure (AUC, Cmax, or trough concentrations).
- Absorption — chelation (tetracycline + Ca²⁺), pH changes (antacids + itraconazole), efflux transporter (P-gp)
- Distribution — protein binding displacement (warfarin + sulfonamides)
- Metabolism — CYP inhibition/induction (most common high-risk interactions)
- Excretion — renal transporter competition (OAT, OCT), urine pH
- Additive — two CNS depressants → excessive sedation
- Synergistic — beta-lactam + aminoglycoside → enhanced bacterial kill
- Antagonistic — naloxone + opioid; beta-agonist + beta-blocker
- Functional — two QT-prolonging drugs → risk of torsades de pointes
CYP450 Interactions
The cytochrome P450 (CYP) enzyme family handles the majority of hepatic (and gut-wall) drug metabolism. Interactions occur when one drug inhibits or induces an enzyme responsible for metabolising a co-administered drug. The FDA CYP interaction table and Flockhart Table (Indiana University) are widely used references.
~50% of drugs. Inhibited by clarithromycin, azole antifungals, grapefruit, ritonavir. Induced by rifampicin, carbamazepine, St. John's wort. Substrates: simvastatin, cyclosporine, tacrolimus, midazolam, apixaban, fentanyl.
~25% of drugs. Inhibited by fluoxetine, paroxetine, bupropion. No known clinically relevant inducers. Substrates: codeine (prodrug), metoprolol, tramadol, risperidone, many TCAs. Significant pharmacogenomic variability (PM vs. UM).
Inhibited by fluconazole, amiodarone. Induced by rifampicin. Substrates: warfarin (S-enantiomer), phenytoin, ibuprofen, losartan, glipizide. CYP2C9*2/*3 alleles reduce activity — see CPIC warfarin guideline.
Inhibited by omeprazole, fluvoxamine. Induced by rifampicin. Substrates: clopidogrel (prodrug — inhibition reduces antiplatelet effect), PPIs, diazepam, escitalopram. CYP2C19 genotype affects clopidogrel efficacy — see CPIC clopidogrel guideline.
Inhibited by ciprofloxacin, fluvoxamine. Induced by smoking, omeprazole. Substrates: clozapine, theophylline, tacrine, caffeine, duloxetine. Smoking cessation raises clozapine levels significantly.
Involved in bupropion, efavirenz, methadone metabolism. Induced by rifampicin (can halve methadone levels). Inhibited by clopidogrel. Significant PGx variability in CYP2B6*6 allele carriers.
- Rapid onset (within hours to days)
- Substrate AUC increases → toxicity risk
- Reversible (except mechanism-based, e.g., grapefruit)
- Dose reduction of substrate often required
- Example: clarithromycin + colchicine → colchicine toxicity
- Slow onset (days to weeks — requires new enzyme synthesis)
- Substrate AUC decreases → efficacy loss
- Offset also slow when inducer stopped
- Dose increase or alternative drug needed
- Example: rifampicin + warfarin → INR falls rapidly
Transporter-Mediated Interactions
Membrane transport proteins govern drug entry into hepatocytes, tubular cells, enterocytes, and the blood–brain barrier. The EMA drug interaction guideline requires assessment of key transporters (P-gp, BCRP, OATP1B1/3, OAT1/3, OCT2) for all new drugs.
| Transporter | Location | Clinical relevance | Key interaction example |
|---|---|---|---|
| P-glycoprotein (P-gp / ABCB1) | Intestine, BBB, kidney, liver | Efflux pump; limits oral absorption of digoxin, dabigatran, loperamide | Quinidine inhibits P-gp → digoxin level doubles |
| BCRP (ABCG2) | Intestine, liver, kidney | Efflux; rosuvastatin, methotrexate, sulfasalazine | Eltrombopag inhibits BCRP → rosuvastatin AUC ↑ 2× |
| OATP1B1/1B3 | Hepatocyte (uptake) | Statin uptake into liver — inhibition raises statin levels | Gemfibrozil + simvastatin → myopathy risk |
| OAT1 / OAT3 | Renal proximal tubule | Secretion of methotrexate, tenofovir, furosemide | Probenecid blocks OAT → methotrexate toxicity |
| OCT2 | Renal proximal tubule | Metformin, dofetilide secretion | Cimetidine inhibits OCT2 → metformin AUC ↑ 50% |
Pharmacodynamic Interactions
Pharmacodynamic interactions occur at the site of action, independent of drug concentration changes. Three subtypes matter clinically:
Effects sum. Two anticoagulants (aspirin + warfarin) increase GI bleeding. Two CNS depressants (alcohol + benzodiazepine) increase respiratory depression. Risk is proportional to dose of each agent.
Combined effect exceeds simple addition. Co-trimoxazole (trimethoprim + sulfamethoxazole) inhibits folate synthesis at sequential steps — synergistic antibacterial. Amphotericin B + azoles: potentially antagonistic, depending on order.
One drug reduces the effect of another. Naloxone reverses opioid-induced respiratory depression. Beta-blockers blunt beta-agonist bronchodilation. Vitamin K reverses warfarin anticoagulation.
QT Prolongation Risk
Combining multiple QT-prolonging drugs increases risk of torsades de pointes (TdP) — a potentially fatal arrhythmia. The CredibleMeds QTDrugs database categorises drugs as Known, Conditional, or Possible risk. Key examples: azithromycin + haloperidol; ondansetron + methadone; fluoroquinolone + Class III antiarrhythmic. Always check QT risk when prescribing psychotropics, antimicrobials, or anti-emetics in combination.
Assessing Clinical Significance
Not all interactions require action. A systematic approach reduces harm while avoiding unnecessary interruptions to therapy:
- 1 Identify the interaction — use validated databases: Drugs.com Interaction Checker, ASHP drug info, UpToDate Lexicomp, or Medscape Interaction Checker.
- 2 Assess severity — contraindicated (avoid) → major (significant harm possible, use alternative) → moderate (monitor) → minor (limited clinical effect).
- 3 Evaluate the patient — narrow TI drugs (warfarin, digoxin, phenytoin, cyclosporine) need more caution. Organ impairment, age extremes, genetic polymorphisms (CYP2D6 PM/UM) amplify risk.
- 4 Choose a management strategy — alternative drug · dose adjustment · timing separation (antacid + quinolone: 2 h apart) · enhanced monitoring (INR, ECG, TDM level).
- 5 Monitor and document — especially on initiation and discontinuation of the precipitant drug. Clinical effect often lags PK change.
FAQ
What are the main types of drug–drug interactions?
Pharmacokinetic (ADME — mainly CYP and transporter) and pharmacodynamic (additive, synergistic, antagonistic effects at the site of action). PK interactions alter drug concentrations; PD interactions alter the pharmacological effect at a given concentration.
Which CYP enzymes are most commonly involved?
CYP3A4 (~50% of drugs), CYP2D6 (~25%), CYP2C9 (warfarin, NSAIDs), CYP2C19 (clopidogrel, PPIs). CYP3A4 and CYP2D6 are responsible for the majority of clinically significant DDIs.
How is clinical significance assessed?
Clinical significance depends on: outcome severity, magnitude of PK change, therapeutic index of the substrate, and patient-specific risk factors. Standard databases classify interactions as contraindicated, major, moderate, or minor.
What is a pharmacodynamic interaction?
A pharmacodynamic interaction occurs when two drugs affect the same physiological target or system, causing additive, synergistic, or antagonistic effects — without necessarily changing drug concentrations. QT prolongation from multiple drugs is a common example.
Where can I check for drug interactions?
Reliable free resources: Drugs.com Interaction Checker, Medscape Drug Interaction Checker, CredibleMeds (QT), and the FDA CYP/transporter table. For clinical practice: Lexicomp, Micromedex, or Clinical Pharmacology.